Ultrasonic Bone Growth Stimulators (Osteogenic Stimulation)

Effective: September 1, 2020

Next Review: April 2021
Last Review: August 2020

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Low-intensity pulsed ultrasound devices are used to transmit energy through tissue as acoustical pressure (sound) waves as a treatment to promote healing of bone fracture sites.

MEDICAL POLICY CRITERIA

I. Low-intensity pulsed ultrasound treatment may be considered medically necessary when either of the following Criteria are met:
   A. Treatment of fracture nonunion of bones of the appendicular skeleton when all of the following Criteria (1.- 5.) are met:
      1. Patient is skeletally mature (see Policy Guidelines); and
      2. At least 3 months have passed since the date of injury or treatment; and
      3. Radiographic evidence on at least 2 serial imaging studies during the most recent 3-month period showing evidence of nonunion or nonhealing; and
      4. The fracture gap is less than or equal to 1 cm; and
      5. The patient can be adequately immobilized.
B. As an adjunct to closed reduction and immobilization in the treatment of certain fresh fractures (defined as within 14 days of the fracture) when all of the following Criteria (1. – 3.) are met:
   1. Patient is skeletally mature (see Policy Guidelines); and
   2. The patient is not a tobacco user OR there is clinical documentation that the patient has been abstinent from tobacco use for at least six weeks prior to stimulation; and
   3. The fracture is one of the following types:
      a. Jones fracture; or
      b. Scaphoid; or
      c. Talar neck; or
      d. Tarsal navicular.

II. The replacement or revision of all or part of an existing stimulator is considered medically necessary when the existing stimulator is malfunctioning, cannot be repaired, and is no longer under warranty.

III. Replacement or revision of all or part of an existing stimulator is considered not medically necessary when Criterion II. is not met.

IV. Low-intensity pulsed ultrasound treatment is considered not medically necessary for any of the following:
   A. Fracture nonunion that does not meet Criterion I.A.;
   B. Fresh fractures that do not meet Criterion I.B.;
   C. Stress fractures (defined as a fatigue-induced fracture resulting from repeated stress over time).

V. Low-intensity pulsed ultrasound treatment is considered investigational for all other conditions, including but not limited to treatment of any of the following:
   A. Fractures or nonunion of bones of the axial skeleton (skull and vertebrae).
   B. Fractures due to bone pathology or tumor/malignancy.
   C. Distraction osteogenesis, osteotomy, congenital pseudoarthrosis, delayed/nonunion of non-spinal joint fusions, or osteonecrosis.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

POLICY GUIDELINES

- Skeletally mature refers to a system of fused skeletal bones, which occurs when bone growth ceases after puberty; for females, this generally occurs around age 16, and for males, around age 18.

- Fractures that have undergone surgical treatment and no longer require surgical intervention should be considered for ultrasound bone growth stimulation applying the Criteria for Fracture Nonunions.
LIST OF INFORMATION NEEDED FOR REVIEW

It is critical that the list of information below is submitted for review to determine if the policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome.

1. History and Physical/Chart notes documenting policy criteria.
2. Documentation of nonunion location, serial radiographs documenting no progressive signs of healing over most recent three months, fracture gap measurement, and documentation supporting skeletal maturity and non-smoking status of the patient.

CROSS REFERENCES

1. Electrical Bone Growth Stimulators (Osteogenic Stimulation), Durable Medical Equipment, Policy No. 83.11

BACKGROUND

Ultrasound is a form of mechanical energy that can be transmitted through tissue as acoustical pressure (sound) waves. As low-intensity waves generated by the device pass over the surface of the skin overlying the fracture, the tissues in the callus may be mechanically stimulated and generate a biochemical response to the stimulation. This may increase blood flow to the fracture site, expression of genes involved in bone healing, secretion of growth factors, and bone matrix ossification, all of which may contribute to fracture healing or nonunion.[1]

REGULATORY STATUS

In 1994, the Sonic Accelerated Fracture Healing System (SAFHS®; renamed Exogen 2000® and since 2006, Exogen 4000+; Bioventus) was approved by the U.S. Food and Drug Administration through the premarket approval process for treatment of fresh, closed, posteriorly displaced distal radius (Colles) fractures and fresh, closed, or grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopedically managed by closed reduction and cast immobilization. In February 2000, the labeled indication was expanded to include the treatment of established nonunions, excluding skull and vertebra. Food and Drug Administration product code: LOF.

BONE FRACTURES

An estimated 7.9 million fractures occur annually in the United States. Most bone fractures heal spontaneously over several months following standard fracture care (closed reduction if necessary, followed by immobilization with casting or splinting). However, approximately 5% to 10% of all fractures have delayed healing, resulting in continued morbidity and increased utilization of health care services.[2] Factors contributing to a nonunion include which bone is fractured, fracture site, the degree of bone loss, time since injury, the extent of soft tissue injury, and patient factors (eg, smoking, diabetes, systemic disease).[3]

FRESH (ACUTE) FRACTURE

While there is no standard definition of a “fresh” fracture, the most common definition is within seven days after the fracture occurs.[4,5] Other studies have defined fresh as less than five days after fracture and as up to 10 days postfracture, and other studies have suggested even more variable timeframes based on fracture location.[6-8] Most fresh closed fractures heal
without complications using standard fracture care (i.e., closed reduction and cast immobilization).

FRACTURE NONUNION

There is no consensus on the definition of nonunions applicable to all fractures, given variations in the bone tissue and fracture characteristics.[3] A 2005 AHRQ Technology Assessment review found that nonunion is most commonly defined as the absence of signs of healing for an additional three months after assessment is made that healing is delayed.[1] These definitions do not reflect the underlying conditions in fractures that affect healing, such as the degree of soft tissue damage, alignment of the bone fragments, vascularity, and quality of the underlying bone stock. There also is variability in the specific radiographic and clinical criteria used to diagnose nonunion. A review of the literature found that 79% of surgeons use radiographic evidence of cortical continuity as the primary means of defining fracture nonunion, and 42% also used weight-bearing and 37% used pain at the fracture site during palpation.[9]

EVIDENCE SUMMARY

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life (QOL), and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of low-intensity pulsed ultrasound (LIPUS) for bone healing, two domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

LOW-INTENSITY PULSED ULTRASOUND

Systematic Reviews

A systematic review (SR) by Schandelmaier (2017) provides a comprehensive overview and analysis of the existing evidence, including 26 RCTs that used LIPUS for bone healing.[10] Given the substantial overlap in the studies included in this SR and others, summarized below, we will primarily focus on the findings of Schandelmaier (2017), which include analyses that highlight the results of RCTs identified as of higher quality. The recently published meta-analysis by Seger (2017) analyzed healing index and average time to union following use of LIPUS in cases of scaphoid nonunion, but it did not report control group comparisons.[11] The systematic review by Lou (2017), focused on fresh fractures and the review by Leighton (2017)
focused on nonunions.\[12,13\] All systematic reviewers acknowledged that the evidence for the use of LIPUS has methodologic limitations.

The study populations in RCTs included by Schandelmaier (2017) examined multiple types of fractures including fresh fractures surgically managed (n=7), fresh fractures not surgically managed (n=6), distraction osteogenesis (n=5), nonunion fractures (n=3), osteotomy (n=3), and stress fractures (n=2). The RCTs had a median population size of 30 patients (range, 8-501 patients). The outcomes examined by this SR emphasized those reported by patients to be most important: functional recovery (eg, time to return to work, time to full weight-bearing); pain reduction; and number of subsequent operations. Additional outcomes included time to radiographic healing, because this may be used by physicians to influence clinical decision making and adverse events associated with LIPUS.

In this SR, two reviewers independently assessed the quality of selected RCTs, using GRADE, a modified Cochrane risk of bias tool. Generation of randomization sequence, concealment of allocation, and blinding of patients, caregivers, and outcome reporting were evaluated in each trial. Each outcome within each trial was assessed for blinding of outcome assessors, loss to follow-up, and additional limitations. Trial authors were contacted if there was uncertainty in the quality assessment. Of the 26 included trials, six were considered to have a low-risk of bias, with the remaining 20 trials considered to have a high-risk of bias. Reasons for high-risk of bias designation included failure to report a method for allocation concealment (15 trials), high or unclear numbers of patients excluded from the analysis (13 trials), unblinded patients (10 trials), and unblinded caregivers or outcome assessors (10 trials). Of the 6 trials rated to be at low-risk of bias, four were conducted in individuals with fresh fracture, three of which were operatively managed tibial fractures.

LOW-INTENSITY PULSED ULTRASOUND FOR FRACTURE NONUNION

Systematic Review

Leighton (2017) reported the results of a SR and meta-analysis of published literature that explored the use of low-intensity pulsed ultrasound as a treatment of nonunions.\[13\] A total of 13 eligible papers, including one RCT, reporting the results of LIPUS for the treatment of 1441 nonunions of the tibia, humerus, radius, ulna and femur, were evaluated. The date range of the literature search was not specified. The quality of the studies was scored using the Methodological Index for Non-Randomized Studies. Quality scores ranged from 5 to 12, with an “ideal” score for a nonrandomized trial being 16. The pooled estimate of effect size for heal rate was 82% (95% CI: 77-87%) for any anatomical site and fracture age of at least 3 months, although statistical heterogeneity was identified across all primary studies (Q=41.2 [df=12], p<0.001, Tau2=0.006, I2=71). With a stricter definition of nonunion as fracture age of at least eight months duration, the pooled estimate of effect size rose to 84% (95% CI: 77%-91.6%) although heterogeneity remained present: Q=21 [df=8], p<0.001, Tau2=0.007, I2=62). No statistically significant difference was detected between upper and lower extremity long bone nonunions in heal rate. Favorable results of LIPUS intervention were obtained when LIPUS was used as an alternative rather than as an adjuvant to surgery.

Seger (2017) published a SR with meta-analysis including five studies focused on scaphoid nonunions in which healing index and average time to union following LIPUS were analyzed.\[11\] Among the 166 nonunions in the analysis, 78.6% (range, 33%-100%) were reported to show healing following LIPUS, with an average time to union of 4.2 months (range, 2.3-5.6 months).
These results lead the authors to conclude that LIPUS may serve as a nonoperative alternative to scaphoid nonunion in certain cases.

Randomized Controlled Trials

Schofer (2010), published the results of a multicenter, double-blinded, sham-controlled RCT of LIPUS in 101 adult patients who had sustained a tibial shaft fracture that subsequently showed inadequate progress toward healing.[14] This RCT was included in the SR by Leighton. Delayed union was defined as a lack of clinical and radiologic evidence of union, bony continuity, or bone reaction at the fracture site for no less than 16 weeks from the index injury or the most recent intervention. Patients were randomized to LIPUS (n=51) or to an inactive sham device (n=50), to be administered 20 minutes a day for 16 weeks. The primary outcome was change in bone mineral density assessed by computed tomography attenuation coefficients. Gap area was a secondary outcome. Intention-to-treat analysis showed that low-intensity pulsed ultrasound improved mean bone mineral density by 34% (90% CI, 14% to 57%) compared with sham treatment. The mean reduction in bone gap area was -0.13 mm2 in the low-intensity pulsed ultrasound group and -0.10 mm2 in the sham group (effect size, -0.47; 95% CI, -0.91 to -0.03 mm2). At the end of 16 weeks, physicians judged 65% of patients in the low-intensity pulsed ultrasound group healed and 46% of the patients in the sham group healed (p=0.07). This trial did not report functional outcomes or pain assessment, limiting the utility of results.

Ricardo (2006) published a blinded RCT evaluating 21 subjects with scaphoid nonunion who were treated with low-intensity pulsed ultrasound or a sham device following a pedicled vascularized bone graft.[15] Time to healing was defined as the number of days from the operation to healing both clinically (solid and not causing tenderness or pain) and radiographically (bridging cortices). All patients were males, with an average age of 26.7 years (range 17-42 years) and an average interval between injury and surgery of 38.4 months (range 3 months-10 years). Follow-up averaged 2.3 years (range 1-4 years). Although all patients achieved fracture union (active and placebo groups) compared with the placebo device (n=11), the active device (n=10) accelerated healing by an average of 38 days (56+/-3.2 days compared with 94+/-4.8 days, P<0.0001).

Nonrandomized Studies

Nolte (2016) conducted a retrospective comparison of patients with metatarsal fractures treated by low-intensity pulsed ultrasound and by surgical techniques.[16] For the comparative analysis, patients from a U.S. Food and Drug Administration (FDA) required LIPUS registry (n=594) were propensity-matched 1:1 with patients treated surgically from a health claims database. The overall heal rates for all types of fractures combined were comparable for LIPUS (97%) and surgery (95%) (p=0.07). After exclusion of registry patients who received surgery, heal rate with LIPUS alone (97.4%) was significantly better (P<0.0097) than the heal rate for matched patients in 2011 (94.2%).

Rutten (2007) published an analysis of 76 individuals with tibial nonunions. Included in the analysis were 71 individuals who were at least 3 months from the last surgical intervention and did not show any healing improvements in the 3 months before ultrasound treatment (average fracture age: 257 days; range: 180-781).[17] All individuals were followed up (average 2.7 years) by questionnaire, or by phone, if needed. There was an overall healing rate of 73%, at an average 184 days to healing (range: 52-739). No difference in healing rate for open or closed fractures was observed.
Section Summary: Fracture Nonunion

The evidence for the use of LIPUS in the treatment of fracture nonunion includes 14 studies, two of which are RCTs, and two additional nonrandomized studies. Two systematic reviews with meta-analyses have evaluated data on LIPUS for fracture nonunion. Shorter healing times compared to sham or no treatment have been identified across these studies, and favorable outcomes in reduction of bone gap size and mineral density have been found with treatment with LIPUS compared to sham treatment. There is sufficient evidence to determine that treatment of fracture nonunion with LIPUS provides improvement in health outcomes in skeletally mature patients.

FRESH FRACTURES

Systematic Review

Lou (2017) conducted a SR with meta-analysis focusing on fresh fractures in adults.[12] The literature search, conducted through November 2016, included 12 studies (N=1099), all of which were included in the Schandelmaier (2017) meta-analysis, except for a small abstract (n=20). The evidence was considered to be of moderate-to-high quality. The pooled results revealed that low-intensity pulsed ultrasound significantly decreased the time to fracture union (standard mean difference [SMD]: 0.65; 95% confidence interval [CI], 1.13 to 0.17), improved the quality of life (SMD: 0.20; 95% CI, 0.03–0.37) without affecting the time to full weight bearing (SMD: 0.76, 95% CI: 1.92 to 0.4), the time to resuming work (SMD: 0.06; 95% CI, 0.14 to 0.27), or the incidence rate of delayed union and nonunion (RR: 1.02; 95% CI, 0.60–1.74). A subgroup analysis demonstrated that the reduction in healing time with low-intensity pulsed ultrasound was not reflected in individuals who underwent surgical intervention. While the authors concluded that individuals with fresh fractures may benefit from the use of low-intensity pulsed ultrasound, there were several methodologic limitations in the trials, including but not limited to the inadequate concealment of treatment allocation, the high loss of follow-up, the unclear age baseline, smoking, or gender status.

Hannemann (2014) published a SR with meta-analysis of 13 RCTs (N=737) comparing pulsed electromagnetic fields (PEMF) or low-intensity pulsed ultrasound (LIPUS) bone growth stimulation with placebo for fresh fractures.[18] Three hundred and fifty-five participants were treated with LIPUS (N=209) or PEMF (N=146), and 382 participants were treated with a placebo device. No significant differences were found in time to radiological union between PEMF or LIPUS and placebo (mean difference = -13.32, 95% CI= -32.71 to 6.06, p=0.18), however, in pooled data analyses, heterogenous results that significantly favored PEMF or LIPUS treatment specifically in non-operatively managed fractures were identified (mean difference = -26.65, 95% CI -50.35 to -2.91, p = 0.03). In addition, pooled analysis of the three studies comparing PEMF or LIPUS with placebo of the upper limb found heterogenous results of significantly reduced time to radiological union in this group compared to control (mean difference = -20.23, 95% CI -32.68 to -7.77, p = 0.001). There was considerable heterogeneity in the outcome parameter of time to radiological union, which is considered a limitation of the study. The authors concluded that bone growth stimulation with LIPUS or PEMF decreases healing time to radiological union for fresh fractures undergoing non-operative treatment and fractures of the upper limb.

Surgically Managed

Randomized Controlled Trials
Included in the SR by Lou was a double-blinded, sham-controlled RCT, the Trial to Re-evaluate Ultrasound in the Treatment of Tibial Fractures (TRUST) published by Busse (2016). This RCT evaluated LIPUS for the treatment of patients who underwent intramedullary nailing for fresh tibial fractures.[19] This is the largest RCT to date, enrolling 501 patients; 250 received a LIPUS device, and 251 received a sham device. Treatment was self-administered for 20 minutes a day until there was radiographic evidence of healing. Coprimary endpoints were radiographic healing and return to function (as measured by the 36-Item Short-Form Health Survey [SF-36] Physical Component Summary score). Both radiographic and functional assessments had to show a clinically important effect for the results to be considered positive. All patients, clinicians, investigators, data analysts, and the industry sponsor were blinded to allocation until data analysis was complete. Patient compliance was considered moderate, with 73% of patients administering over half of all recommended treatments. There was no difference in time to radiographic healing between the treatment groups (hazard ratio, 1.07; 95% CI, 0.86 to 1.34; P=0.55). Additionally, there was no difference in the SF-36 Physical Component Summary scores (mean difference, 0.55; 95% CI, -0.75 to 1.84; P=0.41). A previously conducted pilot double-blind RCT by Busse et al (2014), including 51 subjects not assessed in the 2016 study, also did not find any statistically significant differences in pain reduction, number of subsequent operations, or radiographic healing time.[20]

Tarride et al (2017) provided additional analyses using data from the TRUST trial, comparing healthcare resource use among patients using low-intensity pulsed ultrasound with patients using the sham device.[21] There were no significant differences between groups (11% in patients receiving low-intensity pulsed ultrasound vs. 10% in patients receiving sham) in need for secondary procedures (eg, removal of lock screw, implant exchange or removal). There were also no statistically significant differences in use of physical therapy (44% vs. 46%), use of anticoagulants (42% vs. 36%), or use of nonsteroidal anti-inflammatory drugs (28% vs. 35%) among patients receiving Low-intensity pulsed ultrasound compared with patients receiving sham, respectively.

**Nonsurgically Managed**

**Randomized Controlled Trial**

Lubbert (2008) performed a multicenter, double-blind RCT (n=101) of LIPUS treatment of fresh (<5 days) clavicle shaft fractures.[8] This trial also was included in the SR by Lou. Patients used the low-intensity pulsed ultrasound devices for 20 minutes once daily for 28 days and recorded their subjective feeling as to whether the fracture healed (the primary outcome measure), pain on a visual analog scale, level of daily activities (hours of work, household work, sport), and analgesic use. Patient perception of the day the fracture healed was determined in 92 patients (47 active, 45 placebo); mean time to heal was 26.77 days in the active group and 27.09 days in the placebo group (P=0.91). Between-group differences regarding analgesic use and mean visual analog scale scores for pain also did not differ significantly.

**Section Summary: Fresh Fractures**

Evidence for LIPUS for fresh fractures includes 12 RCTs reporting outcomes from a number of fracture sites including the tibia, radius, lateral malleolus, scaphoid, fifth metatarsal, and clavicle. A SR of these studies concluded that in a pooled analysis, LIPUS decreased the time to fracture union only in non-surgically managed patients, but did not improve time to full weight bearing, time to resuming work, or the incidence rate of delayed union or nonunion. A number of limitations to the trials also were noted, including inadequate concealment of
treatment allocation, high loss of follow-up, the unclear age baseline, and unclear smoking or gender status.

**STRESS FRACTURES**

Gan (2014) evaluated the effectiveness of LIPUS for the improvement of lower limb bone stress injuries.[22] In this prospective, randomized, double-blind, placebo-controlled trial, individuals with a magnetic resonance imaging (MRI)-diagnosed grade II-IV bone stress injury of either the postero-medial tibia, fibula or second, third, or fourth metatarsal were randomized to either active treatment or placebo device for 20 minutes daily for four weeks. A total of 30 participants were initially recruited; 23 participants were included in the final analysis. Six clinical parameters including night pain, pain at rest, pain on walking, pain with running, tenderness, and pain with single leg hop were compared prior to and after the intervention. The investigators reported no significant differences between the treatment and placebo groups for measurements of the six clinical parameters. Regardless of the relatively short duration of four weeks and the small sample size consisting of primarily female participants, low-intensity pulsed ultrasound was found to be ineffective for the healing of lower limb bone stress injuries.

Rue (2004) reported on a double-blind RCT that examined the effects of 20 minutes of daily LIPUS on tibial stress fracture healing outcomes such as pain, function, and resumption of professional and personal activities in 26 military recruits.[23] The delay from onset of symptoms to diagnosis was 32 days in the low-intensity pulsed ultrasound group and 28 days in the placebo group. This trial found no significant difference in healing times between LIPUS treatment and sham, with a mean time of return to duty of 56 days for both groups. The trial was rated with a high-risk of bias in the Schandelmaier (2017) meta-analysis.

**LOW-INTENSITY PULSED ULTRASOUND FOR OTHER CONDITIONS**

**Open Fractures**

There is limited and inconsistent data addressing the efficacy of LIPUS for the treatment of open fractures. Emami (1999) conducted a randomized study of 32 individuals with a fresh tibial fracture that was fixed with an intramedullary rod. Patients underwent additional treatment with an active or inactive ultrasound device.[5] The time to healing was not significantly different in the two groups. These observations are consistent with the meta-analysis conducted by Busse (2002) whose analysis supported the use of LIPUS for fractures treated nonoperatively but no clear benefit in operatively treated fractures.[19] In contrast, Leung (2004) reported a RCT of 30 fractures in 28 individuals with complex tibial fractures treated with internal or external fixation to receive or not receive additional treatment with LIPUS.[24] Based on radiologic assessment, the time to callus formation was significantly less in those in the ultrasound treatment group; however, two individuals in the control group experienced delayed union (12%). Due to the inconsistent results in these two small randomized studies, and the negative results of the meta-analysis, LIPUS is considered not medically necessary for open fractures.

**Osteotomy Sites**

Urita (2013) published a small (n=27) quasi-randomized study (alternating assignment) of LIPUS after ulnar-shortening osteotomy for ulnar impaction syndrome or radial-shortening osteotomy for Kienböck disease.[25] Patients in the LIPUS group received daily 20-minute
treatment for at least 12 weeks postoperatively. Blinded evaluation of radiographic healing showed that LIPUS reduced the mean time to the cortical union by 27% (57 days vs. 76 days) and endosteal union by 18% (121 days vs. 148 days) compared with sham treatment. At the time of endosteal healing, the osteotomy plus LIPUS group and the osteotomy-only group had similar results, as measured using the Modified Mayo Wrist Score and no pain at the osteotomy site. The study was rated at high-risk of bias in the meta-analysis by Schandelmaier (2017).

**Distraction Osteogenesis**

Salem (2014) evaluated the use of LIPUS compared to control in a nonblinded, randomized trial of 21 individuals undergoing callus distraction for posttraumatic tibial defects.[26] Outcomes were examined clinically and radiologically, analyzing callus maturation with a computer-assisted measurement. Use of LIPUS shortened healing by 12 days/cm and the total fixator time by 95 days. The results of this study are limited by the small number of participants and nonblinded study design. Larger randomized, sham-controlled trials of homogeneous study populations are needed to evaluate the efficacy of low-intensity pulsed ultrasound as an adjunct to distraction osteogenesis procedures for any indication.

Dudda (2011) investigated the effect of LIPUS in a prospective RCT of 36 participants (n=16 treatment group, n=20 control group) who underwent distraction osteogenesis (> 2 cm) to the lower extremities.[27] The authors did not specify the location of the bone distraction beyond “right” and “left” lower leg” in either the treatment or control group. Fixation devices included Regazzoni, Ilizarov, and hybrid fixators. Evaluation was performed by standard radiographs every 3 to 4 weeks. Treatment outcomes were reported in measures of the length of the “fixator gestation period”, the distraction consolidation index (the ratio of fixator gestation time in days over the distraction gap size in cm), and the Paley index (ratio of fixator gestation period in months over the distraction gap size in cm). The investigators reported a shorter fixation gestation period by 43.6 days for the treatment group versus the control group, 218.6 versus 262.2 days, respectively, but the statistical significance of this outcome was not reported. The mean distraction consolidation index for the treatment group was 32.8 days/cm and 44.6 days/cm for the control group (P=0.116). The mean Paley index for the treatment versus the control group was 1.09 months/cm and 1.49 months/cm, respectively (P=0.116). The difference between the treatment and control groups in these measures did not reach statistical significance. Limitations of this study include the small number of callus distractions performed, heterogeneity of the population (highly variable patterns of injury and medical treatments performed), and the lack of blinding to treatment.

There are no controlled studies identified in the published literature that specifically address the use of LIPUS as a treatment of fresh fractures of the axial skeletal system, fractures due to bone malignancy, congenital pseudoarthroses, or as an adjunct to spinal fusion. There are no studies in the peer-reviewed literature specifically focused on improved healing rates following uncomplicated bunionectomy procedures (first metatarsal osteotomy) as compared to a period of immobilization and limited weight bearing; in addition, these surgeries are not considered at high risk for post-surgical nonunion.

**PRACTICE GUIDELINE SUMMARY**

The American Academy of Orthopedic Surgeons (AAOS) published a 2010 clinical practice guideline on the treatment of distal radius fractures in which the recommendation for the use of
low-intensity pulsed ultrasound was considered “weak” given the lack of high-quality evidence.[28]

The 2018 National Institute for Health and Care Excellence (NICE) guidelines state “the evidence for low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing raises no major safety concerns. The current evidence on efficacy is very limited in quantity and quality. Therefore, this procedure should only be used in the context of research.”[29]

The 2018 National Institute for Health and Care Excellence (NICE) guidelines state “the evidence for low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures raises no major safety concerns. The current evidence on efficacy is inadequate in quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent and audit or research.”[30]

**SUMMARY**

**FRACTURE NONUNION**

It appears that low-intensity pulsed ultrasound may improve health outcomes for individuals with certain types of fracture nonunion. Evidence-based clinical practice guidelines consider the evidence for the use of low-intensity pulsed ultrasound for the treatment of fracture nonunion to be limited, however, use of low-intensity pulsed ultrasound for the treatment of certain fracture nonunion is widely used. Therefore, the use of low-intensity pulsed ultrasound for the treatment of fracture nonunion is considered medically necessary when Criteria are met.

For patients who do not meet the policy criteria for fracture nonunion, low-intensity pulsed ultrasound is considered not medically necessary because the technology is not considered clinically effective or appropriate for these individuals.

**FRESH FRACTURE**

It appears that low-intensity pulsed ultrasound may improve health outcomes for individuals with certain types of fresh fractures. Evidence-based clinical practice guidelines consider the evidence for the use of low-intensity pulsed ultrasound for the treatment of fresh fractures to be limited, however, use of low-intensity pulsed ultrasound for the treatment of certain fresh fractures is widely used. Therefore, the use of low-intensity pulsed ultrasound for the treatment of fresh fractures is considered medically necessary when Criteria are met.

For patients who do not meet the policy criteria for fresh fracture, low-intensity pulsed ultrasound is considered not medically necessary because the technology is not considered clinically effective or appropriate for these individuals.

**DEVICE REPLACEMENT**

In certain situations, an osteogenic stimulator may no longer be able to perform its basic function due to damage or wear. When a stimulator is out of its warranty period and cannot be repaired adequately to meet the patient’s medical needs, replacement of the device may be medically appropriate. Therefore, replacement of all or part of a low-intensity pulsed
ultrasound stimulator may be considered medically necessary when device replacement Criteria are met.

When a stimulator is in its warranty period or can be repaired or adapted adequately to meet the patient’s medical needs, replacement of the device is not medically appropriate. Therefore, replacement of all or part of a low-intensity pulsed ultrasound stimulator is considered not medically necessary when device replacement Criteria are not met.

STRESS FRACTURES

The evidence for the use of low-intensity pulsed ultrasound for the treatment of stress fractures has not demonstrated the added benefit of the technology on health outcomes. Evidence-based clinical practice guidelines do not recommend the use of low-intensity pulsed ultrasound for the treatment of stress fractures. Therefore, low-intensity pulsed ultrasound for the treatment of stress fractures is considered not medically necessary.

OTHER INDICATIONS

There is not enough evidence to determine if low-intensity pulsed ultrasound improves health outcomes in the treatment of any other conditions. Evidence-based clinical practice guidelines do not recommend the use of low-intensity pulsed ultrasound for any other conditions. Therefore, low-intensity pulsed ultrasound is considered investigational for the treatment of all other conditions, including but not limited to fractures or delayed/nonunion of bones of the axial skeleton, delayed/nonunion of joint fusions, fractures due to bone pathology or tumor/malignancy, distraction osteogenesis, osteotomy, congenital pseudoarthrosis, or osteonecrosis.

REFERENCES


29. Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing. [cited 3/20/2020]; Available from: https://www.nice.org.uk/guidance/IPG622/chapter/1-Recommendations

30. Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures. [cited; Available from: https://www.nice.org.uk/guidance/IPG623/chapter/1-Recommendations

31. "Low Intensity Pulsed Ultrasound Fracture Healing Device." Policy No. 1.01.05

### CODES

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>20979</td>
<td>Low intensity ultrasound stimulation to aid bone healing, noninvasive (nonoperative)</td>
</tr>
<tr>
<td>HCPCS</td>
<td>E0760</td>
<td>Osteogenesis stimulator, low intensity ultrasound, non-invasive</td>
</tr>
</tbody>
</table>

*Date of Origin: April 2020*